FDA approves
cervical cancer treatment

GlaxoSmithKline said on Thursday that U.S. regulators have approved the use of its drug Hycamtin in combination with cisplatin for the treatment of cervical cancer that can't be treated with surgery or radiation therapy. The Food and Drug Administration approval is based on late-stage results that demonstrated a survival advantage by using Hycamtin in combination with cisplatin compared with cisplatin alone. The company is currently developing a vaccine for the human papilloma virus, the leading cause of cervical cancer. Hycamtin is currently marketed in the United States for the treatment of a type of lung cancer. (Reuters)